Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2022-07-08 Declaration of Voting R…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly Information Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of June 30, 2022. This type of regular disclosure regarding the share capital structure and voting rights is a specific regulatory requirement, often falling under general regulatory announcements or specific share/capital change notifications. Since it is a monthly update on the total number of shares and voting rights, it most closely aligns with a notification about the capital structure, but it is not a formal share issue (SHA) or a transaction in own shares (POS). Given the context of regular, mandatory disclosure of share capital structure updates, it fits best under the general regulatory filing category (RNS) or potentially a specific capital structure notification if one were available. However, looking at the definitions, it is a specific regulatory disclosure about the capital base. Since there isn't a perfect fit for 'Monthly Share Capital/Voting Rights Disclosure', and it is a formal regulatory communication, RNS (Regulatory Filings) is the most appropriate fallback, although it is very close to SHA or DVA in theme. Given the focus on the total number of shares and voting rights, which is a fundamental component of capital structure reporting, and the lack of a specific code for this exact monthly report, RNS is the safest general regulatory classification.
2022-07-08 French
Inside Information / Other news releases
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "STATEMENT OF TOTAL VOTING RIGHTS AND SHARES FORMING THE COMPANY'S SHARE CAPITAL" and explicitly references compliance with French Commercial Code articles and regulations from the Autorité des Marchés Financiers (AMF). It provides a table detailing the number of shares outstanding and the total number of voting rights (gross and net) as of a specific date (May 31, 2022). This type of mandatory disclosure regarding the total number of voting rights is a specific regulatory filing requirement, often related to shareholder structure or meeting prerequisites. Among the provided codes, 'DVA' (Declaration of Voting Results & Voting Rights Announcements) is the most appropriate fit, as this statement directly declares the total voting rights available, which is crucial for calculating voting power thresholds and meeting outcomes.
2022-06-09 English
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of a specific date (April 30, 2022). This content directly relates to changes in share capital structure and voting rights disclosure, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a general regulatory filing (RNS). However, since it specifically details the total number of shares and voting rights, which is a key component of capital structure reporting, SHA is the most precise fit among the specific options. It is not a general earnings release (ER), an interim report (IR), or a director's dealing report (DIRS).
2022-06-09 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and is dated June 5, 2022. It announces new clinical data regarding the product NBTXR3, presented at the 2022 American Society for Clinical Oncology (ASCO) annual meeting. This format—a formal announcement detailing recent scientific/clinical updates, often referencing presentations at industry conferences—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/scientific news. Since it focuses on presenting key clinical results (efficacy and safety data from Phase 1b/2 trials) rather than a comprehensive financial overview (10-K/IR) or a management discussion (MDA), the most fitting category is Earnings Release (ER), as these releases often accompany or precede the release of detailed financial results, or serve as the primary vehicle for communicating major operational milestones like clinical data presentations. Given the context of a biotech company presenting trial data, ER is the best fit among the options, although RNS (Regulatory Filings) is a possibility if it were purely a regulatory filing. However, the structure strongly suggests a formal announcement of results, aligning with ER. FY 2022
2022-06-05 French
Inside Information / Other news releases
Earnings Release Classification · 99% confidence The document is explicitly titled "# *PRESS RELEASE*" and announces the reporting of new data at the "2022 Annual Meeting of the American Society for Clinical Oncology (ASCO)". It details clinical trial results (Phase 1b/2 studies for head and neck and rectal cancer) and discusses the company's strategy and product candidate (NBTXR3). This format—a formal announcement of recent operational/clinical news, often released concurrently with a major industry event—is characteristic of an Earnings Release (ER) or a general press release announcing significant, non-periodic operational updates. Since it focuses on clinical data presentation at a conference rather than quarterly financial figures (which would suggest ER or IR), and it is not a full regulatory report (like 10-K or IR), the most fitting category for a press release detailing operational/clinical milestones is the general 'Earnings Release' (ER) category, as these releases often contain the key financial/operational highlights that drive investor interest, even if the primary focus here is clinical data presentation. Given the context of a biotech company, press releases announcing data presentation at major medical meetings are frequently categorized alongside earnings releases as they serve a similar function of providing key periodic updates to investors. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal regulatory filing like 10-K or IR. It is a summary of findings, not the full report itself, making ER the best fit among the provided options for a major, time-sensitive announcement. FY 2022
2022-06-05 English
Informations privilégiées / Autres communiqués
AGM Information Classification · 98% confidence The document is a press release announcing the date, time, and location for the company's 'assemblée générale mixte annuelle' (Annual General Meeting). It explicitly mentions that the notice of meeting, agenda, and resolutions were published in the BALO (Official Legal Announcements Bulletin). This document serves as an announcement related to the AGM proceedings, rather than the detailed materials themselves (like DEF 14A or AGM-R presentation). Since it is an announcement concerning the upcoming AGM, the most appropriate classification is AGM-R, which covers presentations and materials shared during the AGM, or potentially RPA if it were purely announcing the availability of the final materials. Given the focus is the meeting itself, AGM-R is the best fit among the specific options, although it is an announcement *about* the AGM rather than the final materials. However, since the text details the date and location of the AGM, AGM-R is selected over the general RPA/RNS.
2022-06-02 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.